Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 15/20 | 0.60 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.60 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.57 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.57 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683687 | 0.94 | AGTR1 (0.69) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL13937415 | 0.94 | AGTR1 (0.52) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL7308864 | 0.92 | AGTR1 (0.63) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL13714565 | 0.90 | AGTR1 (0.47) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL7304823 | 0.90 | AGTR1 (0.49) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL8847979 | 0.89 | AGTR1 (0.58) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL8847844 | 0.88 | AGTR1 (0.58) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL9091939 | 0.88 | AGTR1 (0.45) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL9092788 | 0.88 | AGTR1 (0.46) | AGTR1AGTR2PPARGKDM4EABCC3 | |
| SCHEMBL8848172 | 0.87 | AGTR1 (0.58) | AGTR1AGTR2PPARGKDM4EABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | claimed |
| US-11931341-B2 | Compositions and methods for the treatment and prevention of muscular dystrophy | UNIVERSITY OF LOWA RESEARCH FOUNDATION (US) | 2024-03-19 | — | — | US | claimed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | claimed |
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-09-14 | — | — | US | claimed |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-08 | — | — | US | claimed |
| US-11634413-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-04-25 | — | — | US | claimed |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-22 | — | — | US | claimed |
| US-20220242836-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-08-04 | — | — | US | claimed |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-07 | — | — | US | claimed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | claimed |
| US-20060217421-A1 | Fortifier | TORAY INDUSTRIES, INC. (JP) | 2006-09-28 | — | — | US | claimed |
| WO-2006099058-A2 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| WO-2006093864-A1 | CARDIOVASCULAR COMPOUNDS COMPRISING NITRIC OXIDE ENHANCING GROUPS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2006-09-08 | — | — | WO | claimed |
| EP-1627638-A1 | FORTIFIER | TORAY INDUSTRIES, INC. (JP) | 2006-02-22 | — | — | EP | claimed |
| EP-1115399-A1 | USE OF A PHARMACEUTICAL COMPOSITION CONTAINING, IN COMBINATION, AN ANTAGONIST OF THE ANGIOTENSIN II AT 1? RECEPTORS AND INDOMETHACIN FOR MAKING A MEDICINE TREATING CHRONIC GLOMERULONEPHRITIS | Sanofi-Aventis (FR) | 2001-07-18 | — | — | EP | claimed |
| WO-2000037075-A1 | COMBINATION OF AN AT1 ANGIOTENSIN II RECEPTOR ANTAGONIST AND AN IMMUNOSUPPRESSANT | SANOFI-SYNTHELABO (FR) | 2000-06-29 | — | — | WO | claimed |
| WO-2000002556-A1 | USE OF A PHARMACEUTICAL COMPOSITION CONTAINING, IN COMBINATION, AN ANTAGONIST OF THE ANGIOTENSIN II AT1 RECEPTORS AND INDOMETHACIN FOR MAKING A MEDICINE TREATING CHRONIC GLOMERULONEPHRITIS | SANOFI-SYNTHELABO (FR) | 2000-01-20 | — | — | WO | claimed |
| EP-0502314-B1 | Benzimidazol derivatives, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1998-05-20 | — | — | EP | claimed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285340-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 5/4885AGTR2 11/4885PPARG 4731/4885 |
| US-11931341-B2 | Compositions and methods for the treatment and prevention of muscular dystrophy | AGTR2, AGTR1, MUSK | AGTR1 2/4885AGTR2 1/4885PPARG 469/4885 |
| US-11718591-B2 | Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof | MME, CTSC, REN | AGTR1 25/4885AGTR2 42/4885PPARG 3055/4885 |
| US-20220242836-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | AGTR1 25/4885AGTR2 40/4885PPARG 3023/4885 |
| US-20220106300-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 4/4885AGTR2 13/4885PPARG 4587/4885 |
| US-11634413-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 4/4885AGTR2 13/4885PPARG 4587/4885 |
| US-20220298173-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | AGTR1 4/4885AGTR2 11/4885PPARG 4816/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | AGTR1 2/4885AGTR2 1/4885PPARG 631/4885 |
| US-20060217421-A1 | Fortifier | REN, PTGER1, GPR132 | AGTR1 8/4885AGTR2 22/4885PPARG 77/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 4/4885AGTR2 9/4885PPARG 4814/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | AGTR1 5/4885AGTR2 11/4885PPARG 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.